Edit Background Image
African American female scientist wearing protective gear working in a laboratory

PhRMA launches first ever industry-wide principles on clinical trial diversity

In November 2020, PhRMA member companies launched the first ever industry-wide principles on clinical trial diversity. These principles build on our commitment to earn trust and address the systemic issues that deter Black and Brown communities from participating in clinical trials, so that people who want to participate, can.

Read the Principles
Edit Background Image

Diversity is critical to the work we do.

Diversity is essential to a robust innovation ecosystem that can create new medicines for those who need them. America’s biopharmaceutical companies are pushing for necessary, positive and long-term change to better meet the needs of Black and Brown America.

READ THE LETTER
Edit Background Image

PhRMA statement on presidential executive order restricting diversity training

Our companies have committed to pushing for necessary, positive, long-term change to better address the needs of diverse communities. It is why we spoke out against an executive order restricting workplace diversity training programs.

READ THE STATEMENT

In the Spotlight

Systemic racism is as real as any disease, and our industry is not immune

by Courtney Christian

This month, PhRMA published our commitment to racial equity and inclusion in the New York Times as well as in the Informer and the AfroAmerican, DC-based, Black-owned newspapers. This public declaration is an important milestone for our industry as we continue to take concrete steps to address systemic racism and work towards a more equitable future…
Read More
Addressing health inequities: Biopharmaceutical companies are rising to the occasion

by Dr. Freda Lewis-Hall

My uncle was a paraplegic because of a polio infection when he was six years old. By the time I reached the same age, I was so inspired by the care my uncle received that I decided I wanted to be a doctor. Years later when I entered Howard University College of Medicine in 1976…
READ MORE
PhRMA will continue to advocate for equity within our industry

by Yolanda Hutchins

When I first started at PhRMA two and a half years ago, our organization was just starting to talk about how we could increase and activate our commitment to diversity & inclusion (D&I). As senior director of talent acquisition, some of my first tasks were to build an inhouse recruiting team and develop a D&I strategy for the organization…
Read More
Three ways the pharmaceutical industry can positively impact health equity

by Guest Contributor

As a physician scientist, I have dedicated my life’s work to creating healthier communities globally through drug development, advocacy, empowerment and engagement. Born in a rural, segregated Arkansas town of 18,000 people, many lived below the poverty line — both then and now — regardless of race...
Read More

Related Resources

PhRMA's Racial Justice Principles

WASHINGTON, D.C. (July 28, 2020)

Diversity is essential to a robust innovation ecosystem that can create new medicines for those who need them. America’s biopharmaceutical companies are pushing for necessary, positive and long-term change to better meet the needs of Black and Brown America.

That means:

  • Open, honest, real conversations about racial equity and what it means to have a culture of inclusion.
  • Expanding opportunities to work and succeed in our industry.
  • Advancing policy solutions and research to better address health disparities.
  • Diversifying our business practices to better invest in Black and Brown America.
  • Earning trust and addressing systemic issues that deter Black and Brown communities from participating in clinical trials, so that people who want to participate, can.
DOWNLOAD THE PRINCIPLES